Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial


Sumary of Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial:

  • Many vaccines are being trialed against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the enveloped virus causing the current coronavirus disease 2019 (COVID-19) pandemic..
  • Newer and more effective vaccines are urgently required due to the rapid emergence of highly transmissible and perhaps more virulent virus lineages that often confer immune escape..
  • During this time, hundreds of thousands of severe COVID-19 cases will need to be treated, making new vaccines a priority to prevent the overwhelming of health services..
  • A new preprint research paper posted to the medRxiv* server reports the results of the first human trial of the prefusion stabilized SARS-CoV-2 spike vaccine MVC-COV1901 in Taiwan..
  • Stabilized vaccine design A vaccine must use an immunogenic antigen in the right conformation to elicit a protective neutralizing response..
  • In the current case, SARS-CoV-2 mediates attachment to the host cell via a receptor called the angiotensin-converting enzyme 2 (ACE2) by its spike protein..
  • To stabilize it in the prefusion state, a pair of proline residues is added to obtain S-2P – the stabilized prefusion S ectodomain of the spike protein..
  • Study details Related Stories The phase I study of MVC-COV1901 included 45 healthy adults between 20 and 49 years, who received two doses each, but in high, medium, and low dosages..
  • The spike-specific immunoglobulin G (IgG) antibody titer was markedly increased after the boost dose, with peak geometric mean titers (GMT) at 7,000 for the low-dosage group, 7,7000 for the medium dosage, and 11,000 for the high-dose groups, respectively..
  • The study thus shows that the MVC-COV1901 vaccine, a stabilized prefusion spike-based adjuvanted vaccine, is safe, well-tolerated, and immunogenic in healthy adults up to 49 years…

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.